Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


A new vaccine therapy for brain cancer


MEDIA RELEASE

29 November 2012

A new vaccine therapy for brain cancer

What do you do when you are faced with terminally ill patients that want to trial a promising immunotherapy but are too sick to provide the immune cells necessary for it to work? If you are Wellington-based Neurosurgeon Mr Martin Hunn, you head back to the laboratory and find another way.

Glioblastoma multiforme (GBM) is a highly aggressive brain tumour, with an extremely poor prognosis.

The standard treatments for GBM are surgery, radiotherapy and chemotherapy, but the tumour rapidly becomes resistant to these therapies, making it ultimately fatal in almost all cases. There is an urgent need to develop novel therapies for this disease.

“We hypothesised that by acting through entirely different mechanisms, therapies that activate the immune system might succeed in attacking GBM tumours where standard treatments have failed,” says Mr Hunn.

Immunotherapy has been explored as a potential treatment option for brain cancers for some time. Here in New Zealand, Mr Hunn, along with colleagues at Wellington Hospital and the Malaghan Institute, recently completed a Phase I GBM vaccine trial at Wellington Hospital, the outcomes of which will be available next year.

The vaccines used in these trials are typically created from the patient’s tumour tissue – the target, and dendritic cells - the immune cells that direct the anti-tumour immune response.

“The problem however is that some GBM patients are so unwell it can be difficult to isolate enough dendritic cells from their blood to prepare a vaccine,” says Mr Hunn.

In parallel to his clinical work, Mr Hunn therefore undertook some laboratory-based research in collaboration with Associate Professor Ian Hermans and colleagues from the Malaghan Institute, to see if they could simplify their approach by removing the need for dendritic cells to be present in the vaccine.

Their research, published recently in the peer-reviewed international journal Clinical Cancer Research, shows that a vaccine consisting of only tumour cells and an immune-boosting adjuvant is an effective treatment for brain tumours (gliomas) in a mouse model.

“Our research has shown that we can evoke a tumour-specific, long-lasting immune response that is strong enough to kill glioma tumours by targeting the activation of dendritic cells already present inside the mouse,” says Mr Hunn. “In some instances we saw the complete disappearance of tumour lesions as detected by magnetic resonance imaging.”

One of the reasons Mr Hunn thinks this new immunotherapy approach has such great promise is because of the adjuvant included in the vaccine to boost the anti-tumour immune response – a compound derived from marine sponges called alpha-galactosylceramide (alpha-GalCer).

While this new vaccine therapy has been developed in mice, early indications are that GBM cancer patients have the immune system ‘machinery’ required for the therapy to work equally well in humans.

”We believe our research has identified a simple vaccine that could be an effective treatment for a group of patients who currently face an extremely poor prognosis,” says Mr Hunn.

This research was supported by the Cancer Society of New Zealand, the Neurological Foundation of New Zealand, the Wellington Medical Research Foundation and Just Paterson Real Estate. Mr Hunn was supported by a New Zealand Health Research Council Clinical Fellowship, the Royal Australasian College of Surgeons and the Surgical Research Trust.

Research Publication Details
Hunn MK, Farrand KJ, Broadley KW, Weinkove R, Ferguson P, Miller RJ, Field CS, Petersen T, McConnell MJ, Hermans IF Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma. Clin Cancer Res, 2012 Nov 12 [Epub ahead of print]

About the Malaghan Institute of Medical Research
The Malaghan Institute of Medical Research is New Zealand’s leading vaccine and immunology research institute and is based at Victoria University of Wellington’s Kelburn campus. The Institute operates independently and is a charitable trust. Researchers at the Malaghan Institute are focused on developing innovative ways to harness the strength and potency of the immune system, the body’s own natural defence against disease, to treat cancer, asthma and allergy, arthritis, multiple sclerosis and infectious disease.


Mr Martin Hunn

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Science: Hookworm Discovery At Malaghan Institute

Professor Graham Le Gros has led a team which has stimulated both innate and memory responses to the parasite, discovering along the way the unexpected behaviour of one particular immune cell, in Hookworm, one of the world’s most devastating tropical ... More>>

Business: Provinces Urged To Make Full Use Of New Air Services

Provincial New Zealand has been urged to use new air services to Auckland or risk losing them either partially or completely. The stark warning was issued today by Far North mayor John Carter at a ceremony at Kaitaia airport to mark the final Air ... More>>

Mobile: 2degrees To Credit All Calls And SMS To Nepal

In the wake of the devastating earthquake in Nepal in the weekend, 2degrees will be crediting all calls and SMS messages made to mobiles and landlines in Nepal from Friday 24th April until midnight Wednesday 29th April. More>>

Scoop Business: Alex Swney Pleads Guilty To $2.5M Fraud Charge

Alex Swney, former chief executive of the Auckland city centre business association Heart of the City, has pleaded guilty to dishonestly using documents to obtain $2.5 million. More>>

ALSO:

Petrol Burns Prices: Second Consecutive Quarterly Fall For CPI

The consumers price index (CPI) fell 0.3 percent in the March 2015 quarter, following a 0.2 percent fall in the December 2014 quarter, Statistics New Zealand said today. The last time the CPI showed two consecutive quarterly falls was in the December 1998 and March 1999 quarters. More>>

ALSO:

Scoop Business: NZ Broadcasters Launch Battle Against Global Mode ISPs

New Zealand broadcasters have confirmed they’ve launched legal proceedings against internet service providers who give customers’ access to “global mode”, which allows customers access to offshore online content, claiming it breaches the local content providers’ copyright. More>>

ALSO:

Sanford: Closure Of Christchurch Mussel Processing Plant Confirmed

The decision comes after a period of consultation with the 232 staff employed at the Riccarton site, who were told on 9 April that Sanford was considering the future of mussel processing in Christchurch. Recent weather patterns had impacted on natural spat (offspring) supply... More>>

ALSO:

Price Of Cheese: Dairy Product Prices Fall To The Lowest This Year

Dairy product prices fell in the latest GlobalDairyTrade auction, hitting the lowest level in the 2015 auctions so far, as prices for milk powder and butter slid amid concern about the outlook for commodities. More>>

ALSO:

Houston, We Have An Air Route: Air New Zealand To Fly Direct To The Heart Of Texas

Air New Zealand will fly its completely refitted Boeing 777-200 aircraft between Auckland and Houston up to five times a week opening up the state of Texas as well as popular nearby tourist states such as Louisiana and Florida. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news